Medpace (NASDAQ:MEDP) versus Personalis (NASDAQ:PSNL) Head-To-Head Comparison

Personalis (NASDAQ:PSNL) and Medpace (NASDAQ:MEDP) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Personalis and Medpace, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1	5	4	0	2.30
Medpace	0	9	3	0	2.25

Personalis presently has a consensus target price of $14.54, suggesting a potential downside of 10.80%. Medpace has a consensus target price of $595.20, suggesting a potential downside of 5.62%. Given Medpace’s higher possible upside, analysts plainly believe Medpace is more favorable than Personalis.

Profitability

This table compares Personalis and Medpace’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Medpace	17.67%	110.15%	24.84%

Earnings and Valuation

This table compares Personalis and Medpace”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.65 million	24.50	-$81.27 million	($1.09)	-14.95
Medpace	$2.53 billion	6.96	$451.12 million	$17.06	36.97

Medpace has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Personalis has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.

Insider & Institutional Ownership

61.9% of Personalis shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 4.2% of Personalis shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Medpace beats Personalis on 10 of the 14 factors compared between the two stocks.

About Personalis

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.